Is patent foramen ovale a modifiable risk factor for stroke recurrence?

Stroke

Volumn 41, Issue 10 SUPPL. 1, 2010, Pages

  Kent, David M ^a   Thaler, David E ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cryptogenic stroke; patent foramen ovale; risk factors for stroke; secondary stroke prevention

Indexed keywords

CONFERENCE PAPER; DISEASE ASSOCIATION; HEART RIGHT LEFT SHUNT; HUMAN; PARADOXICAL EMBOLISM; PATENT FORAMEN OVALE; PATHOGENESIS; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; STROKE; COMPLICATION; SECONDARY PREVENTION;

FORAMEN OVALE, PATENT; HUMANS; RECURRENCE; RISK FACTORS; SECONDARY PREVENTION; STROKE;

EID: 77958009441     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.595140     Document Type: Conference Paper

References (17)

1. Meissner I, Khandheria BK, Heit JA, Petty GW, Sheps SG, Schwartz GL, Whisnant JP, Wiebers DO, Covalt JL, Petterson TM, Christianson TJ, Agmon Y. Patent foramen ovale: innocent or guilty? evidence from a prospective population-based study. J Am Coll Cardiol. 2006;47: 440-445.
2. Tong DC, Becker KJ. Patent foramen ovale and recurrent stroke: closure is the best option: no. Stroke. 2004;35:804-805.
3. Meier B. Closure of patent foramen ovale: technique, pitfalls, complications, and follow up. Heart. 2005;91:444-448.
4. Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation. 2005;112:1063-1072.
5. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002;105: 2625-2631.
6. Almekhlafi MA, Wilton SB, Rabi DM, Ghali WA, Lorenzetti DL, Hill MD. Recurrent cerebral ischemia in medically treated patent foramen ovale: a meta-analysis. Neurology. 2009;73:89-97.
7. Serena J, Marti-Fabregas J, Santamarina E, Rodriguez JJ, Perez-Ayuso MJ, Masjuan J, Segura T, Gallego J, Davalos A. Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke. 2008;39:3131-3136.
8. Lamy C, Giannesini C, Zuber M, Arquizan C, Meder JF, Trystram D, Coste J, Mas JL. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. Stroke. 2002;33:706-711.
9. Weimar C, Holle DN, Benemann J, Schmid E, Schminke U, Haberl RL, Diener HC, Goertler M. Current management and risk of recurrent stroke in cerebrovascular patients with right-to-left cardiac shunt. Cerebrovasc Dis. 2009;28:349-356.
10. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Coste J, Patent Foramen Ovale and Atrial Septal Aneurysm Study Group. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001;345:1740-1746.
11. Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryp-togenic stroke. incidental or pathogenic? Stroke. 2009;40:2349-2355.
12. Kent DM, Trikalinos TA, Thaler DE. Patent foramen ovale and cryp-togenic stroke. N Engl J Med. 2008;358:1519-1520.
13. Mattle HP, Meier B, Nedeltchev K. Prevention of stroke in patients with patent foramen ovale. Int J Stroke. 2010;5:92-102.
14. Berthet K, Lavergne T, Cohen A, Guize L, Bousser MG, Le Heuzey JY, Amarenco P. Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke. 2000;31:398-403.
15. Mugge A, Daniel WG, Angermann C, Spes C, Khandheria BK, Kronzon I, Freedberg RS, Keren A, Denning K, Engberding R. Atrial septal aneurysm in adult patients: a multicenter study using transthoracic and transesophageal echocardiography. Circulation. 1995;91:2785-2792.
16. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med. 2003;139: 753-760.
17. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. J Am Med Assoc. 2007;298:1209-1212.